一线化疗-话题@MedSci

#一线化疗#

28篇内容 | 755人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1924715, encodeId=81591924e15de, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Clin Cancer Res：一线化疗加用大剂量维C是否可改善转移性结直肠癌患者预后, objectType=article, longId=735294, objectId=f0bae3529407, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0bae3529407, replyNumber=0, likeNumber=39, createdTime=2023-04-16, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0bae3529407, moduleTitle=Clin Cancer Res：一线化疗加用大剂量维C是否可改善转移性结直肠癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0bae3529407)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924714, encodeId=fee21924e1442, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Thorac Cancer：广泛期小细胞肺癌(ED-SCLC)患者标准一线化疗治疗后使用阿帕替尼维持治疗可进一步延长生存, objectType=article, longId=294109, objectId=be7a294109e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be7a294109e3, replyNumber=0, likeNumber=49, createdTime=2022-03-26, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be7a294109e3, moduleTitle=Thorac Cancer：广泛期小细胞肺癌(ED-SCLC)患者标准一线化疗治疗后使用阿帕替尼维持治疗可进一步延长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be7a294109e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924712, encodeId=76fd1924e12ab, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=BMC Cancer：真实世界研究比较二线afatinib (阿法替尼)对比化疗治疗一线化疗后进展的晚期肺鳞状细胞癌患者的疗效, objectType=article, longId=291850, objectId=7bef291850d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bef291850d8, replyNumber=0, likeNumber=39, createdTime=2022-04-16, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bef291850d8, moduleTitle=BMC Cancer：真实世界研究比较二线afatinib (阿法替尼)对比化疗治疗一线化疗后进展的晚期肺鳞状细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bef291850d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924716, encodeId=1b851924e16f5, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=新药联合一线化疗能否为患者带来获益？, objectType=article, longId=735966, objectId=5648e35966cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5648e35966cc, replyNumber=0, likeNumber=30, createdTime=2023-06-01, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5648e35966cc, moduleTitle=新药联合一线化疗能否为患者带来获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5648e35966cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924711, encodeId=ad491924e110b, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, objectType=article, longId=221370, objectId=59592213e0c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59592213e0c8, replyNumber=0, likeNumber=39, createdTime=2022-06-25, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59592213e0c8, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59592213e0c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924710, encodeId=2f4e1924e1051, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=不可切除转移性结直肠癌-一线化疗解读, objectType=article, longId=220762, objectId=e0ae220e6263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0ae220e6263, replyNumber=0, likeNumber=42, createdTime=2022-09-23, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0ae220e6263, moduleTitle=不可切除转移性结直肠癌-一线化疗解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0ae220e6263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924708, encodeId=48931924e08f3, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响, objectType=article, longId=219077, objectId=4bf12190e736, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf12190e736, replyNumber=0, likeNumber=44, createdTime=2022-05-31, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf12190e736, moduleTitle=Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bf12190e736)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924709, encodeId=82501924e09d7, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, objectType=article, longId=219199, objectId=9d6e219199ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6e219199ce, replyNumber=0, likeNumber=41, createdTime=2022-05-07, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6e219199ce, moduleTitle=Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6e219199ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924713, encodeId=c00c1924e13c1, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=BMC Cancer：Eribulin（艾日布林）改善HER2阴性晚期乳腺癌患者一线化疗开始后的总生存, objectType=article, longId=293647, objectId=7e8929364eca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8929364eca, replyNumber=0, likeNumber=42, createdTime=2022-05-06, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8929364eca, moduleTitle=BMC Cancer：Eribulin（艾日布林）改善HER2阴性晚期乳腺癌患者一线化疗开始后的总生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e8929364eca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924706, encodeId=00e11924e061c, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Clin Cancer Res：基于智能分析的基因特征可预测采用奥沙利铂一线化疗的晚期结直肠癌预后, objectType=article, longId=205907, objectId=246f20590eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246f20590eea, replyNumber=0, likeNumber=45, createdTime=2021-07-04, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246f20590eea, moduleTitle=Clin Cancer Res：基于智能分析的基因特征可预测采用奥沙利铂一线化疗的晚期结直肠癌预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246f20590eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924707, encodeId=41e41924e07a0, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Lancet oncol：复发性/转移性头颈鳞状细胞癌患者的两种一线化疗方案对比！, objectType=article, longId=208161, objectId=dc7d20816104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7d20816104, replyNumber=0, likeNumber=44, createdTime=2021-03-24, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7d20816104, moduleTitle=Lancet oncol：复发性/转移性头颈鳞状细胞癌患者的两种一线化疗方案对比！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7d20816104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924705, encodeId=bcbf1924e051a, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=NEJM：Veliparib联合一线化疗治疗高级别浆液性卵巢癌, objectType=article, longId=184965, objectId=4d61184965a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d61184965a6, replyNumber=0, likeNumber=47, createdTime=2020-10-23, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d61184965a6, moduleTitle=NEJM：Veliparib联合一线化疗治疗高级别浆液性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d61184965a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924704, encodeId=eba51924e0440, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=乳腺癌病例：辅助内分泌原发耐药患者晚期一线化疗后氟维司群维持治疗的重要性, objectType=article, longId=182240, objectId=4ee518224089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee518224089, replyNumber=0, likeNumber=38, createdTime=2020-05-23, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee518224089, moduleTitle=乳腺癌病例：辅助内分泌原发耐药患者晚期一线化疗后氟维司群维持治疗的重要性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ee518224089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924703, encodeId=310a1924e0394, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Blood：二代测序检测CLL一线化疗后的微小残留病灶的敏感性更高, objectType=article, longId=179948, objectId=227b1e994890, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=227b1e994890, replyNumber=0, likeNumber=40, createdTime=2019-12-17, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=227b1e994890, moduleTitle=Blood：二代测序检测CLL一线化疗后的微小残留病灶的敏感性更高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=227b1e994890)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924702, encodeId=2af21924e02f5, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=Lancet Haematology：Nivolumab联合一线化疗治疗急性髓系白血病, objectType=article, longId=177285, objectId=c6391e7285a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6391e7285a6, replyNumber=0, likeNumber=53, createdTime=2020-02-19, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6391e7285a6, moduleTitle=Lancet Haematology：Nivolumab联合一线化疗治疗急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6391e7285a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924699, encodeId=6e06192469929, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=2018 CCO指南：小细胞肺癌的初期管理以及胸部放疗和一线化疗的作用, objectType=article, longId=144863, objectId=049a144863d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=049a144863d5, replyNumber=0, likeNumber=23, createdTime=2018-11-28, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=049a144863d5, moduleTitle=2018 CCO指南：小细胞肺癌的初期管理以及胸部放疗和一线化疗的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=049a144863d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924700, encodeId=5b361924e0067, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=J Gastroenterology：吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者预后风险评估, objectType=article, longId=150952, objectId=32681509528a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32681509528a, replyNumber=0, likeNumber=33, createdTime=2018-12-31, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32681509528a, moduleTitle=J Gastroenterology：吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者预后风险评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32681509528a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924701, encodeId=baeb1924e01f9, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=J Gastroenterology：吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者治疗结果的预测因子分析, objectType=article, longId=161798, objectId=7b44161e9849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b44161e9849, replyNumber=0, likeNumber=43, createdTime=2020-01-25, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b44161e9849, moduleTitle=J Gastroenterology：吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者治疗结果的预测因子分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b44161e9849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924698, encodeId=4437192469846, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, objectType=article, longId=124108, objectId=397812410839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397812410839, replyNumber=0, likeNumber=0, createdTime=2018-01-23, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397812410839, moduleTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397812410839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1924694, encodeId=bf601924694e0, content=<a href='/topic/show?id=74ed1941207' target=_blank style='color:#2F92EE;'>#一线化疗#</a>, objectTitle=ESMO OPEN：无驱动基因的晚期 NSCLC在一线化疗失败后，何去何从, objectType=article, longId=92709, objectId=06fd92e097b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fd92e097b, replyNumber=0, likeNumber=41, createdTime=2018-02-21, rootId=0, userName=okhuali, userId=ea6321, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fd92e097b, moduleTitle=ESMO OPEN：无驱动基因的晚期 NSCLC在一线化疗失败后，何去何从, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fd92e097b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

一线化疗

2020-05-29

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Clin Cancer Res：一线化疗加用大剂量维C是否可改善转移性结直肠癌患者预后

2023-04-16

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Thorac Cancer：广泛期小细胞肺癌(ED-SCLC)患者标准一线化疗治疗后使用阿帕替尼维持治疗可进一步延长生存

2022-03-26

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

BMC Cancer：真实世界研究比较二线afatinib (阿法替尼)对比化疗治疗一线化疗后进展的晚期肺鳞状细胞癌患者的疗效

2022-04-16

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

新药联合一线化疗能否为患者带来获益？

2023-06-01

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性

2022-06-25

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

不可切除转移性结直肠癌-一线化疗解读

2022-09-23

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Int J Urol：铂基一线化疗对转移性尿路上皮癌患者总生存的影响

2022-05-31

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Front Oncol：一线化疗的基础上联合PD-1抑制剂可改善晚期胆道癌患者的预后

2022-05-07

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

BMC Cancer：Eribulin（艾日布林）改善HER2阴性晚期乳腺癌患者一线化疗开始后的总生存

2022-05-06

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Clin Cancer Res：基于智能分析的基因特征可预测采用奥沙利铂一线化疗的晚期结直肠癌预后

2021-07-04

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Lancet oncol：复发性/转移性头颈鳞状细胞癌患者的两种一线化疗方案对比！

2021-03-24

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

NEJM：Veliparib联合一线化疗治疗高级别浆液性卵巢癌

2020-10-23

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

乳腺癌病例：辅助内分泌原发耐药患者晚期一线化疗后氟维司群维持治疗的重要性

2020-05-23

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Blood：二代测序检测CLL一线化疗后的微小残留病灶的敏感性更高

2019-12-17

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

Lancet Haematology：Nivolumab联合一线化疗治疗急性髓系白血病

2020-02-19

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

2018 CCO指南：小细胞肺癌的初期管理以及胸部放疗和一线化疗的作用

2018-11-28

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

J Gastroenterology：吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者预后风险评估

2018-12-31

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

J Gastroenterology：吉西他滨联合顺铂作为一线化疗的晚期胆道癌患者治疗结果的预测因子分析

2020-01-25

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2018-01-23

okhuali (审核中...)

前往app查看评论内容

#一线化疗#

ESMO OPEN：无驱动基因的晚期 NSCLC在一线化疗失败后，何去何从

2018-02-21

科室
- - 订阅+
  - 更多科室
工具
服务